Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment
暂无分享,去创建一个
D. Heymann | Aude I. Ségaliny | B. Dizier | A. Mohamadi | R. Brion | J. Amiaud | C. Charrier | A. Lokajczyk | Rachel Lanel | C. Boisson‐Vidal
[1] Sanjay Kumar,et al. Src-mediated Post-translational Regulation of Endoglin Stability and Function Is Critical for Angiogenesis* , 2014, The Journal of Biological Chemistry.
[2] Y. Henrotin,et al. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation. , 2014, Seminars in arthritis and rheumatism.
[3] D. Heymann,et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. , 2014, Cancer letters.
[4] Zhiwei Wang,et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. , 2013, European journal of cancer.
[5] T. Hagemann,et al. Tumour-associated macrophages and cancer. , 2013, Current opinion in pharmacology.
[6] M. Mehler,et al. Receptor-type Protein-tyrosine Phosphatase ζ Is a Functional Receptor for Interleukin-34* , 2013, The Journal of Biological Chemistry.
[7] N. Udagawa,et al. IL-34 and CSF-1: similarities and differences , 2013, Journal of Bone and Mineral Metabolism.
[8] K. Hirschi,et al. Regulation of endothelial cell differentiation and specification. , 2013, Circulation research.
[9] A. Oldberg,et al. Biological functions of iduronic acid in chondroitin/dermatan sulfate , 2013, The FEBS journal.
[10] T. Byzova,et al. Inflammation and oxidative stress in angiogenesis and vascular disease , 2013, Journal of Molecular Medicine.
[11] N. Ifrah,et al. IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ , 2013, PloS one.
[12] D. Heymann,et al. Mechanistic study of the proangiogenic effect of osteoprotegerin , 2013, Angiogenesis.
[13] A. Sica,et al. Macrophage plasticity and polarization in tissue repair and remodelling , 2013, The Journal of pathology.
[14] L. Juliano,et al. A motif within the N-terminal domain of TSP-1 specifically promotes the proangiogenic activity of endothelial colony-forming cells. , 2012, Biochemical pharmacology.
[15] M. Soellner,et al. Development of a highly selective c-Src kinase inhibitor. , 2012, ACS chemical biology.
[16] J. Gómez-Reino,et al. Expression and modulation of adipolin/C1qdc2: a novel adipokine in human and murine ATDC-5 chondrocyte cell line , 2012, Annals of the rheumatic diseases.
[17] M. Diamond,et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia , 2012, Nature Immunology.
[18] J. Monahan,et al. Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts , 2011, Rheumatology International.
[19] Andrew H. Beck,et al. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. , 2011, The American journal of pathology.
[20] D. Heymann,et al. Bone sarcomas: pathogenesis and new therapeutic approaches , 2011 .
[21] J. Guan,et al. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. , 2011, Advanced drug delivery reviews.
[22] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[23] P. Fagenholz,et al. Hypoxia and inflammation. , 2011, The New England journal of medicine.
[24] K. Buki,et al. The Critical Role of IL-34 in Osteoclastogenesis , 2011, PloS one.
[25] I. Laurendeau,et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony‐forming cells properties , 2011, Journal of thrombosis and haemostasis : JTH.
[26] Anne-Marie Cleton-Jansen,et al. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.
[27] J. Monahan,et al. Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood. , 2010, Cytokine.
[28] D. Heymann,et al. Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis , 2010, The Journal of pathology.
[29] S. Hirohashi,et al. Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma , 2010, Molecular Cancer Therapeutics.
[30] A. Maity,et al. M-CSF Signals through the MAPK/ERK Pathway via Sp1 to Induce VEGF Production and Induces Angiogenesis In Vivo , 2008, PloS one.
[31] L. Williams,et al. Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome , 2008, Science.
[32] F. Fauvel-Lafève,et al. Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[33] D. Noonan,et al. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.
[34] K. Alitalo,et al. Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.
[35] Christopher Autry,et al. Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor* , 2007, Journal of Biological Chemistry.
[36] W. Dai,et al. Polo-like Kinases Inhibited by Wortmannin , 2007, Journal of Biological Chemistry.
[37] Y. Iwashita,et al. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. , 2006, Surgery.
[38] O. Razorenova,et al. Akt1 in Endothelial Cell and Angiogenesis , 2006, Cell cycle.
[39] E. Stanley,et al. Colony-stimulating factor-1 in immunity and inflammation. , 2006, Current opinion in immunology.
[40] D. Benisvy,et al. Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. , 2005, Biochemical pharmacology.
[41] F. Pixley,et al. CSF-1 regulation of the wandering macrophage: complexity in action. , 2004, Trends in cell biology.
[42] J. Pollard,et al. Role of infiltrated leucocytes in tumour growth and spread , 2004, British Journal of Cancer.
[43] I. Shiojima,et al. Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.
[44] X. Sastre,et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. , 2002, European cytokine network.
[45] S. L. Warren,et al. pp60(c-src) modulates microvascular endothelial phenotype and in vitro angiogenesis. , 2001, Experimental and molecular pathology.
[46] C. Hecquet,et al. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF , 2001, Oncogene.
[47] D. Trono,et al. A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.
[48] W. Wiktor-Jedrzejczak,et al. Impaired tumor growth in colony‐stimulating factor 1 (CSF‐1)‐deficient, macrophage‐deficient op/op mouse: Evidence for a role of CSF‐1‐dependent macrophages in formation of tumor stroma , 1996, International journal of cancer.
[49] S. Aizawa,et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice , 1995, Nature.
[50] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[51] J. Jacobson,et al. Endothelial FAK as a therapeutic target in disease. , 2012, Microvascular research.
[52] Lianchun Wang,et al. Endothelial heparan sulfate in angiogenesis. , 2010, Progress in molecular biology and translational science.
[53] R. Lidereau,et al. Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study , 2005, Breast Cancer Research and Treatment.